PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Retatrutide — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Retatrutide (LY3437943) is a single peptide that agonizes three receptors: glucagon, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). · pmid:35985340

Mechanism

In obese mice, glucagon-receptor-driven increases in energy expenditure added to the reduced calorie intake driven by its GIP and GLP-1 activity. · pmid:35985340

History

In a 48-week phase 2 trial of 338 adults with obesity, mean body weight fell by up to 24.2% on the highest dose, against 2.1% on placebo. · pmid:37366315

Identity

No public registry record is shown for this page: PubChem gave no record that proves it is this substance.

Where the evidence actually sits

Emerging100%

Proportion of the 2 claims about Retatrutide standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. (2022) · emergingTriple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. (2023) · emerging20222023

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Retatrutide yet.

Dose evidence, rung by rung

No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier

    nothing resolved on this rung

  3. Observational evidence · resolved human data at the emerging tier: thin, or contested
    • LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. · pmid 35985340 · 2022
    • Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. · pmid 37366315 · 2023
  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.